EMBARGOED FOR RELEASE
Wednesday, June 8, 2011
Elizabeth Laur, (414) 276-2145, firstname.lastname@example.org
MDS Press Room: Metro Toronto Convention Centre, South Building, Room 705
Note to media: See abstract 902
Polysomnographic findings in sleep disturbed Parkinson's disease patients
provide diagnostic and disease progression measurement tools
TORONTO - A study evaluating subjective sleep disturbances in patients with advanced stages of Parkinson's disease (PD) and those findings with polysomnographic measures was presented today at The Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders.
Sleep disturbances frequently occur in PD patients and are not always attributable to a nocturnal lack of dopaminergic treatment. Often, patient and/or caregivers' reports do not yield sufficient information for identifying the correct diagnosis as a prerequisite for efficient treatment. To better understand various sleep disturbances in PD, Dr. Friederike Sixel-Doring of Kassel, Germany investigates sleep efficiency.
The study investigated 463 patients with reports of a relevant sleep disturbance by patient and/or caregiver; daytime vigilance problems; written informed consent to video-supported polysomnography (vPSG) and scientific evaluation of data. Video-supported polysomnography was used and analysis of demographic and clinical data was performed.
Cynthia Comella, MD, of Rush University Medical Center in Chicago, Illinois, USA states, "This abstract is significant in that it confirms previous work demonstrating the high frequency of sleep disorders in Parkinson Disease patients in a large group of patients using polysomnography."
Results show that PD patients in advanced stages of the disease show reduced sleep efficiency, sleep fragmentation, increased periodic leg movements (PLM) indices, and reduced slow wave sleep. Almost half (46%) were found to be affected by REM Behavior Disorder (RBD) and over one third (35%) were diagnosed with a sleep-related breathing disorder. RBD in neurodegeneration was found not only to be a preclinical marker, but also a relevant clinical finding in advanced stages of the disease.
About the 15th International Congress of Parkinson's Disease and Movement Disorders:
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,200 physicians and medical professionals from 74 countries will be able to view over 1,100 scientific abstracts submitted by clinicians from around the world.
About The Movement Disorder Society:
The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about The Movement Disorder Society, visit www.movementdisorders.org.